Zobrazeno 1 - 10
of 825
pro vyhledávání: '"Johannes, Oldenburg"'
Autor:
Christian Qvigstad, Lars Q. Sørensen, Geir E. Tjønnfjord, Pål André Holme, Ingrid Pabinger, Cedric Hermans, Roseline d’Oiron, Robert Klamroth, Johannes Oldenburg, Natascha Marquardt, Peter Staritz, Olga Katsarou, Uri Martinowitz, Aharon Lubetsky, Gili Kenet, Annarita Tagliaferri, Maria Elisa Mancuso, Roger Schutgens, Pål André HolmE, Jerzy Windyga, Irena Zupan, Victor Jimenez Yuste, Ramiro Nunez, Philippe de Moerloose, Erik Berntorp, Jan Astermark, Campbell Tait, Gerry Dolan
Publikováno v:
Research and Practice in Thrombosis and Haemostasis, Vol 8, Iss 5, Pp 102514- (2024)
Background: People with hemophilia often experience pain and suffer from comorbidities related to their bleeding disorder. Consequently, unemployment due to disability is prevalent among people with hemophilia. Objectives: To explore associations bet
Externí odkaz:
https://doaj.org/article/bbbcde5173814e1f8d9095c20136a013
Autor:
Muhammad Ahmer Jamil, Rawya Al-Rifai, Nicole Nuesgen, Janine Altmüller, Johannes Oldenburg, Osman El-Maarri
Publikováno v:
Frontiers in Genetics, Vol 15 (2024)
Introduction: Coagulation Factor VIII (FVIII) plays a pivotal role in the coagulation cascade, and deficiencies in its levels, as seen in Hemophilia A, can lead to significant health implications. Liver sinusoidal endothelial cells (LSECs) are the ma
Externí odkaz:
https://doaj.org/article/7213597cbc6f4b008dd82651c72b8c20
Autor:
Richard Lemons, Michael Wang, Julie Curtin, Lynda Mae Lepatan, Christoph Male, Flora Peyvandi, Mario von Depka Prondzinski, Rongrong Wang, William McKeand, Wilfried Seifert, Johannes Oldenburg
Publikováno v:
TH Open, Vol 08, Iss 01, Pp e155-e163 (2024)
Introduction Recombinant fusion protein linking coagulation factor IX (FIX) with albumin (rIX-FP) has been shown to be an effective, well-tolerated treatment for patients with severe hemophilia B who had previously received factor replacement therapy
Externí odkaz:
https://doaj.org/article/9b8f1fd5ab434c34948cf4c09b501cde
Autor:
Barbara Preisler, Behnaz Pezeshkpoor, Anja Merzenich, Sandra Ohlenforst, Heiko Rühl, Vytautas Ivaškevičius, Ute Scholz, Hagen Bönigk, Wolfgang Eberl, Barbara Zieger, Anna Pavlova, Johannes Oldenburg
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 4, p 2384 (2024)
Congenital factor VII (FVII) deficiency is a rare genetic bleeding disorder characterized by deficient or reduced activity of coagulation FVII. It is caused by genetic variants in the F7 gene. We aimed to evaluate the rate of detection of pathogenic
Externí odkaz:
https://doaj.org/article/2b277c9610dd4be19f21749ffa1e7139
Autor:
Carmen Escuriola Ettingshausen, Cedric Hermans, Pål A. Holme, Ana R. Cid, Kate Khair, Johannes Oldenburg, Claude Négrier, Jaco Botha, Aurelia Lelli, Jerzy Windyga
Publikováno v:
Therapeutic Advances in Hematology, Vol 14 (2023)
Background: The bypassing agent, activated prothrombin complex concentrate [aPCC, FEIBA (factor VIII inhibitor bypass activity); Baxalta US Inc, a Takeda company, Lexington, MA, USA], is indicated for the treatment of bleeding episodes, perioperative
Externí odkaz:
https://doaj.org/article/8d1f01490a1242c6b4f52dbc1424e3df
Autor:
Jens Müller, Nasim Shahidi Hamedani, Hannah L. McRae, Heiko Rühl, Johannes Oldenburg, Bernd Pötzsch
Publikováno v:
ACS Omega, Vol 7, Iss 35, Pp 30801-30806 (2022)
Externí odkaz:
https://doaj.org/article/bad1bd09eb4f4f59bb384dd9dfa4ea22
Autor:
Johannes Oldenburg, Susan Halimeh, Georgina W. Hall, Robert Klamroth, Pascual Marco Vera, Martina Jansen, Mary Mathias
Publikováno v:
TH Open, Vol 07, Iss 02, Pp e110-e116 (2023)
Background The efficacy, safety, and immunogenicity of each of Octapharma's factor VIII (FVIII) products, Nuwiq, octanate, and wilate, have been investigated in previously untreated patients (PUPs) with severe hemophilia A in prospective clinical tri
Externí odkaz:
https://doaj.org/article/2ee1e59b90904ba28b4e04d4f62e900a
Autor:
Nasim Shahidi Hamedani, Felix Lucian Happich, Eva-Maria Klein, Heiko Rühl, Günter Mayer, Johannes Oldenburg, Jens Müller, Bernd Pötzsch
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-11 (2022)
Abstract Activated protein C (APC) is a serine protease with anticoagulant and cytoprotective activities which make it an attractive target for diagnostic and therapeutic applications. In this work, we present one-step activation of APC from a commer
Externí odkaz:
https://doaj.org/article/4baba1e3aa6644ab833ea7b0573e83b9
Autor:
Janine Becker-Gotot, Mirjam Meissner, Vadim Kotov, Blanca Jurado-Mestre, Andrea Maione, Andreas Pannek, Thilo Albert, Chrystel Flores, Frank A. Schildberg, Paul A. Gleeson, Birgit M. Reipert, Johannes Oldenburg, Christian Kurts
Publikováno v:
The Journal of Clinical Investigation, Vol 132, Iss 22 (2022)
A major complication of hemophilia A therapy is the development of alloantibodies (inhibitors) that neutralize intravenously administered coagulation factor VIII (FVIII). Immune tolerance induction therapy (ITI) by repetitive FVIII injection can erad
Externí odkaz:
https://doaj.org/article/a91c4628ebc24941b2a4147590a1116b
Autor:
Michael U. Callaghan, Elina Asikanius, Michaela Lehle, Johannes Oldenburg, Johnny Mahlangu, Marianne Uguen, Sammy Chebon, Rebecca Kruse‐Jarres, Víctor Jiménez‐Yuste, Midori Shima, Peter Trask, Christine L. Kempton, Craig M. Kessler, Gallia G. Levy, Flora Peyvandi
Publikováno v:
Research and Practice in Thrombosis and Haemostasis, Vol 6, Iss 6, Pp n/a-n/a (2022)
Abstract Background Bleeding in people with hemophilia A can be life threatening, and intra‐articular bleeds can result in joint damage. Most clinical studies focus on treated bleeds, while bleeds not treated with coagulation factor(s) (untreated b
Externí odkaz:
https://doaj.org/article/e0003f2e961e49a1b507a404d3f16f57